1. Home
  2. STKS vs SGMT Comparison

STKS vs SGMT Comparison

Compare STKS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

HOLD

Current Price

$2.09

Market Cap

74.3M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.68

Market Cap

204.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKS
SGMT
Founded
2004
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
74.3M
204.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
STKS
SGMT
Price
$2.09
$5.68
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$4.38
$27.00
AVG Volume (30 Days)
38.7K
735.0K
Earning Date
03-09-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$820,588,000.00
N/A
Revenue This Year
$23.94
N/A
Revenue Next Year
$5.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
51.57
N/A
52 Week Low
$1.70
$1.73
52 Week High
$5.26
$11.41

Technical Indicators

Market Signals
Indicator
STKS
SGMT
Relative Strength Index (RSI) 51.04 41.55
Support Level $2.23 $5.02
Resistance Level $2.41 $6.15
Average True Range (ATR) 0.18 0.36
MACD -0.03 -0.04
Stochastic Oscillator 28.13 42.27

Price Performance

Historical Comparison
STKS
SGMT

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: